Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.
Journal: Future oncology (London, England)
Published: December 23, 2025
Representativeness of Patients With Lung Cancer in an Integrated Health Care Delivery System.
Journal: The Permanente journal
Published: July 09, 2024
Showing 1-2 of 2
Last Updated: 09/26/2026